U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
FORM 5
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
( ) Check box if no longer subject to Section 16.
Form 4 or Form 5 obligations may continue. See Instructions 1(b).
( ) Form 3 Holdings Reported
( ) Form 4 Transactions Reported
1. Name and Address of Reporting Person
Moyer, Albert J.
Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612
U.S.A.
2. Issuer Name and Ticker or Trading Symbol
Allergan, Inc.
AGN
3. IRS or Social Security Number of Reporting Person (Voluntary)
4. Statement for Month/Year
December, 1995
5. If Amendment, Date of Original (Month/Year)
February, 1996
6. Relationship of Reporting Person to Issuer (Check all applicable)
( ) Director ( ) 10% Owner (X) Officer (give title below) ( ) Other
(specify below)
Corporate Vice President and Chief Financial Officer
<TABLE>
<CAPTION>
___________________________________________________________________________________________________________________________________
Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
___________________________________________________________________________________________________________________________________|
1. Title of Security |2. |3. |4.Securities Acquired (A) |5.Amount of |6.Dir |7.Nature of Indirect |
|Transaction| or Disposed of (D) | Securities |ect | Beneficial Ownership |
|Date |Code| | Beneficially |(D)or | |
| | | | A/| | Owned at |Indir | |
| | | Amount | D | Price | End of Year |ect(I)| |
___________________________________________________________________________________________________________________________________|
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Common Stock | | | | | |2,000 |D | |
- -----------------------------------------------------------------------------------------------------------------------------------|
Common Stock |(1) |R (1|15 |A |(1) |15 |D | |
| |) | | | | | | |
- -----------------------------------------------------------------------------------------------------------------------------------|
Common Stock |(2) |J (2|98 |A |(3) |98 |I |By 401(k) Trust |
| |) | | | | | | |
- -----------------------------------------------------------------------------------------------------------------------------------|
___________________________________________________________________________________________________________________________________|
<CAPTION>
___________________________________________________________________________________________________________________________________
Table II -- Derivative Securitites Acquired, Disposed of, or Beneficially Owned |
___________________________________________________________________________________________________________________________________|
1.Title of Derivative |2.Con |3. |4. |5.Number of De |6.Date Exer|7.Title and Amount |8.Price|9.Number |10.|11.Nature of|
Security |version |Transaction rivative Secu |cisable and| of Underlying |of Deri|of Deriva |Dir|Indirect |
|or Exer |Date |Code| rities Acqui |Expiration | Securities |vative |tive |ect|Beneficial |
|cise Pr | | | red(A) or Dis |Date(Month/| |Secu |Securities |(D)|Ownership |
|ice of | | | posed of(D) |Day/Year) | |rity |Benefi |or | |
|Deriva | | | |Date |Expir| | |ficially |Ind| |
|tive | | | | A/|Exer-|ation| Title and Number | |Owned at |ire| |
|Secu | | | | D |cisa-|Date | of Shares | |End of |ct | |
|rity | | | Amount | |ble | | | |Year |(I)| |
___________________________________________________________________________________________________________________________________|
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
___________________________________________________________________________________________________________________________________|
</TABLE>
Explanation of Responses:
(1) Shares were acquired from 3/10/95 through 12/8/95 under the Allergan, Inc.
Dividend Reinvestment and Stock Purchase Plan at prices ranging
from $28.25 to $31.625 per
share.
(2) Shares were acquired during the fiscal year under the Allergan, Inc.
Savings and Investment Plan at prices ranging from $26.375 to $33.125 per
share, in transactions that were exempt from Section 16(b) by virtue of old
Rule 16a-8(b). The information presented is as of December 31, 1995.
SIGNATURE OF REPORTING PERSON
/s/ Albert J. Moyer
DATE
9/16/96
